TY - JOUR T1 - β-Blockers Reduced the Target Lesion Revascularization After Percutaneous Coronary Intervention Using an Everolimus-eluting Stent JF - In Vivo JO - In Vivo SP - 416 LP - 423 DO - 10.21873/invivo.12719 VL - 36 IS - 1 AU - TATSUYA FUJINAMI AU - TAKASHI ASHIKAGA AU - KATSUYUKI HOSHINA AU - TARO SASAOKA AU - KEN KURIHARA AU - SHUNJI YOSHIKAWA AU - HIROSHI INAGAKI AU - TETSUO SASANO Y1 - 2022/01/01 UR - http://iv.iiarjournals.org/content/36/1/416.abstract N2 - Background/Aim: The effect of β-adrenergic blockers on everolimus-eluting stent (EES) implantation is unknown. We aimed to investigate how β-blockers affect the outcomes of EES by using the Tokyo-MD PCI registry data and analyse real-world data in this drug-eluting stent era in Japan. Patients and Methods: We selected 1,899 patients who underwent EES implantation. We compared patients with β-blocker administration versus those without, at follow-up regarding the incidence rate of ischemia-driven target lesion revascularization (ID-TLR), all-cause death, cardiac death, acute myocardial infarction (AMI), and stent thrombosis (ST). Results: Patients in the β-blocker group had higher coronary risks than those in the non-β-blocker group. Although no significant difference was observed in the five-year incidence of all-cause death, cardiac death, AMI, and ST between the two groups, the incidence of ID-TLR was significantly lower in the β-blocker group (4.5% vs. 6.6%; p=0.04). β-Blocker administration (hazard ratio=0.61; p=0.016) was negatively associated with ID-TLR via multivariate analysis. Conclusion: β-Blocker administration reduced ID-TLR after percutaneous coronary intervention using an EES despite the greater comorbid risks and more severe disease lesions. ER -